Chantal Valiquette

Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis

Daphne Yee, Chantal Valiquette, Marthe Pelletier et al. · American Journal of Respiratory and Critical Care Medicine · 2003 · 833 citations

Drug Safety, Compromise Treatment, Pulmonary Tuberculosis +15

Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults

Dick Menzies, Mênonli Adjobimey, Rovina Ruslami et al. · New England Journal of Medicine · 2018 · 368 citations · Full text

Safety and Side Effects of Rifampin versus Isoniazid in Children

Thierno Diallo, Mênonli Adjobimey, Rovina Ruslami et al. · New England Journal of Medicine · 2018 · 155 citations · Full text

Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials

Jonathon R. Campbell, Anete Trajman, Victoria J. Cook et al. · The Lancet Infectious Diseases · 2019 · 63 citations

Drug Safety, Adverse Events, Pulmonary Tuberculosis +9

Effectiveness and cost-effectiveness of a health systems intervention for latent tuberculosis infection management (ACT4): a cluster-randomised trial

Olivia Oxlade, Andrea Benedetti, Mênonli Adjobimey et al. · The Lancet Public Health · 2021 · 34 citations · Full text